New research shows that 46% of generic drugs from the European Union (EU) critical list of medicines are supplied by just one provider.

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

DelveInsight's Transmucosal Drugs Market Insights report provides the current and forecast market analysis, individual ...

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...

Alvotech and Teva Pharmaceuticals said on Tuesday that the U.S. FDA has accepted for review a Biologics License Application ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Europe active pharmaceutical ingredients (API) market was valued at $ 49.4 billion in 2022 and will grow by 6.8% annually over 2022-2032, d riven by rising adoption of biologics in disease management, ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 70 tables and 52 figures, this 132-page report ?Europe Small Molecule API Market 2022-2032 by Source (Synthetic, ...

The 10-year UK gilt yield fell -1.9 bp to 4.457% ... closed up more than +20% after announcing it has entered into a settlement agreement with Teva Pharmaceuticals to resolve patent litigation.